Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
5.54
+0.36 (6.95%)
At close: Sep 2, 2026, 4:00 PM EDT
5.54
0.00 (0.00%)
After-hours: Sep 2, 2026, 7:30 PM EDT

Seres Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
55135142181698765
Market Cap Growth
-66.78%-5.13%-21.59%-74.06%-8.81%-65.78%
Enterprise Value
96172169223541461
Last Close Price
5.5414.8816.6228.00112.00166.60

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-23.631043.26---
PS Ratio
29.25170.61---5.28
PB Ratio
1.583.0410.29-4.0364.715.82
P/TBV Ratio
1.593.0410.29-64.715.82
P/FCF Ratio
-155.62----
P/OCF Ratio
-120.51---114.40

EV Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EV/Sales Ratio
51.05218.29---3.18
EV/FCF Ratio
-199.11----

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
1.641.886.65-4.4315.080.37
Debt / FCF Ratio
-95.91----
Net Debt / Equity Ratio
1.190.844.41-1.58-1.74-1.84
Net Debt / EBITDA Ratio
-0.55-0.41-0.52-0.370.114.13
Net Debt / FCF Ratio
-0.8043.01-0.41-0.560.0883.91
Asset Turnover
0.020.01---0.42
Quick Ratio
2.042.400.861.302.123.53
Current Ratio
2.112.560.941.782.283.69
Return on Equity (ROE)
-66.57%19.64%---258.04%-42.83%
Return on Assets (ROA)
-39.85%-42.25%-30.43%-34.48%-31.96%-11.55%
Return on Capital Employed (ROCE)
-95.90%-79.10%-123.10%-75.10%-68.40%-23.70%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-40.79%4.23%0.10%-62.84%-35.85%-8.57%
FCF Yield
-93.14%0.64%-105.01%-69.26%-34.20%-0.38%
Buyback Yield / Dilution
-10.79%-14.16%-21.40%-18.44%-17.86%-14.93%
SEC Filings: 10-K · 10-Q